Targeted Asthma Therapy

MedLearning2017

About this app

Asthma is a complex and heterogeneous chronic disease that manifests differently across patient populations, influenced by factors such as age, ethnicity, and comorbid conditions. This program explores the underlying role of type 2 inflammation in asthma pathophysiology and highlights how biomarkers—including eosinophil counts, fractional exhaled nitric oxide (FeNO), and IgE levels—can inform a more personalized approach to treatment. Participants will examine emerging evidence supporting the use of biomarker testing to define asthma phenotypes and optimize therapeutic strategies.

Building on the latest Global Initiative for Asthma (GINA 2025) recommendations, this provides guidance on assessing disease severity, evaluating comorbidities, and identifying patients most likely to benefit from biologic therapy. Clinical data and practical decision-making frameworks will be reviewed that compare anti-IgE, anti–IL-5/5R, anti–IL-4/13, and anti–TSLP biologics, emphasizing their safety, efficacy, and demonstrated benefits in reducing exacerbations and improving lung function.

What’s new

Initial Release